Vortosiran
Vortosiran (RBD4059) is a siRNA that inhibits the synthesis of coagulation factor XI (FXI). Vortosiran shows potent inhibitory activity against mouse FXI transcripts with an IC50 of 69 pM; it exerts similar effects on common FXI transcripts from humans and monkeys, with an IC50 of 59 pM. Vortosiran is internalized via ASGPR-mediated endocytosis, subsequently regulating mRNA translation to suppress FXI synthesis. Vortosiran exhibits antithrombotic activity without impairing hemostatic function. Vortosiran can be used in research related to intravascular thrombosis.
For research use only. We do not sell to patients.
- Purity : 97.76%
- CAS No.: 3061406-99-0
- Formula: C463H620F7N154O291P39S6
- Molecular Weight:14532.10
-
Storage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Biological Activity
Description
|
FXI |
ASGPR |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:female C57BL/6J mice[2]
-
Dosage:1, 3 and 9 mg/kg
-
Administration:s.v.; single dose
-
Result:Prevented arterial and venous thrombosis, but tail bleeding did not prolong.
Chemical Information
-
CAS No. 3061406-99-0
-
Appearance Solid
-
Molecular Weight 14532.10
-
Formula C463H620F7N154O291P39S6
-
Color White to off-white
-
SMILES
[Vortosiran]
-
Synonyms
RBD4059
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2242 KB)
References
[1]. Gabrielsen A, et al. RNA interference therapy targeting coagulation factor XI: a first-in-human trial of RBD4059 (vortosiran). Blood advances. 2026 Apr 14;10(7):2541-2548. [Content Brief]
[3]. Yuan H, et al. Beyond traditional anticoagulants: exploring the future of thromboembolism treatment with FXI inhibitors. Front Immunol. 2026 Oct 5;17:1925585. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)